AR079689A1 - IMIDAZO DERIVATIVES [1,2A] PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THEMSELVES IN MYELOPROLIFERATIVE DISORDERS, LEUKEMIA AND IMMUNOLOGICAL AND INFLAMMATORY DISEASES. - Google Patents

IMIDAZO DERIVATIVES [1,2A] PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THEMSELVES IN MYELOPROLIFERATIVE DISORDERS, LEUKEMIA AND IMMUNOLOGICAL AND INFLAMMATORY DISEASES.

Info

Publication number
AR079689A1
AR079689A1 ARP100104869A ARP100104869A AR079689A1 AR 079689 A1 AR079689 A1 AR 079689A1 AR P100104869 A ARP100104869 A AR P100104869A AR P100104869 A ARP100104869 A AR P100104869A AR 079689 A1 AR079689 A1 AR 079689A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
heteroaryl
substituted
cyano
Prior art date
Application number
ARP100104869A
Other languages
Spanish (es)
Inventor
Santacana Lluis Miquel Pages
Rodriguez Jacob Gonzalez
Paul Robert Eastwood
Victor Giulio Matassa
Tana Jordi Bach
Moll Joan Taltavull
Javaloyes Juan Francisco Caturla
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR079689A1 publication Critical patent/AR079689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Reivindicacion 1: Un compuesto de formula (1), o una sal farmacéuticamente aceptable, o solvato, o N-oxido o estereoisomero del mismo, para uso en el tratamiento de un estado patologico o enfermedad susceptible de mejorar por inhibicion de quinasas Janus (JAK) donde, m es 0 o un numero entero de 1 a 3; Z es un átomo de oxígeno o un grupo NR5; X e Y independientemente representan un átomo de nitrogeno o un grupo -CR9, donde al menos uno de X e Y representa un átomo de nitrogeno; cada uno de R1, R2, R3, R4 y R9 independientemente representa un átomo de hidrogeno, halogeno, ciano, alquilo lineal o ramificado C1-8, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, hidroxialquilo C1-4, cicloalquilo C3-10, cicloalquenilo C3-10, alquil C1-4-cicloalquilo C3-7, arilo monocíclico o policíclico C5-14, un grupo heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, un grupo heterocíclico de 5 a 14 miembros que contiene a menos un heteroátomo seleccionado de O, S y N, un grupo bicíclico que contiene un grupo arilo o heteroarilo monocíclico C5-9 directamente unido a un grupo cicloalquilo o heterocíclico de 5 a 9 miembros, donde dicho grupo heteroarilo o heterocíclico contiene al menos un heteroátomo seleccionado de O, S y N, un grupo aza-bicicloalquilo que tiene hasta 12 átomos de carbono o un grupo aza-bicicloalquenilo que tiene hasta 12 átomos de carbono, en donde los grupos alquenilo, alquinilo, haloalquilo, hidroxialquilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterocíclico, bicíclico, aza-bicicloalquilo y aza-bicicloalquenilo están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de los sustituyentes Ra, y los grupos alquilo están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de Rb; o R1, R2, R3, R4 y R9 independientemente representan un grupo -SR13, -SOR13, -S(O)2R13, -S(O)2NR13R14, -NR13S(O)2R14, -NR13S(O)2NR14, -OR13, -C(O)OR13, -O-C(O)R13, -C(O)-(CH2)n-R13, -NR13R14, -C(O)-(CH2)n-NR13R14, -NR13C(O)-(CH2)n-R14 o un grupo -NR13C(O)-(CH2)n-NR14R15, en donde cada n es 0, 1 o 2; o en el que caso en que dos grupos -CR9 adyacentes están presentes, los dos grupos -CR9 adyacentes y los átomos de carbono a los que están unidos forman opcionalmente un grupo C5-12 grupo arilo o un grupo heteroarilo, cicloalquilo o heterocíclico de 4 a 12 miembros, donde dichos grupos heteroarilo y heterocíclico contienen al menos un heteroátomo seleccionado de O, S y N, donde dichos grupos arilo, heteroarilo, cicloalquilo y heterocíclico están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de un átomo de halogeno, un grupo alquilo lineal o ramificado C1-6, un grupo arilo monocíclico o policíclico C5-14, heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, o heterocíclico de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, en donde los sustituyentes alquilo, arilo, heteroarilo y heterocíclico están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de un átomo de halogeno, un grupo hidroxi, ciano, alquilo lineal o ramificado C1-6 o un grupo haloalquilo C1-4; R5 representa un átomo de hidrogeno, un grupo alquilo lineal o ramificado C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados de un grupo hidroxi, ciano, haloalquilo C1-4, hidroxialquilo C1-4, cicloalquilo C3-10, un grupo fenilo o un anillo heterocíclico saturado de 6 miembros que contiene N, o R5 representa un grupo -S(O)2R10, un grupo -S(O)2NR10R11, -C(O)OR10, -C(O)-(CH2)n-R10 o -C(O)-(CH2)n-NR10R11; R6 y R7cada uno independientemente representa un átomo de hidrogeno o un grupo alquilo lineal o ramificado C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados de un grupo hidroxi, ciano, haloalquilo C1-4, hidroxialquilo C1-4, alcoxi C1-4, alcoxicarbonilo C1-4, cicloalquilo C3-7, un grupo fenilo o un anillo heterocíclico que contiene N, saturado, de 6 miembros; R8 representa un átomo de hidrogeno, halogeno, un grupo ciano, alquilo lineal o ramificado C1-6, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, hidroxialquilo C1-4, -alquil C1-6-alcoxi C1-4, cicloalquilo C3-10, cicloalquenilo C3-10, arilo monocíclico o policíclico C5-14, un grupo heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, un grupo heterocíclico de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, heterocicloalquil C3-7 cetona que contiene 1, 2 o 3 átomos de nitrogeno, un grupo bicíclico que contiene un grupo arilo o heteroarilo monocíclico C5-9 directamente unido a un grupo cicloalquilo o heterocíclico de 5 a 9 miembros, donde dicho grupo heteroarilo o heterocíclico contiene al menos un heteroátomo seleccionado de O, S y N, un grupo aza-bicicloalquilo que tiene hasta 12 átomos de carbono o un grupo aza-bicicloalquenilo que tiene hasta 12 átomos de carbono, en donde los grupos alquenilo, alquinilo, haloalquilo, hidroxialquilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterocíclico, heterocicloalquil cetona, bicíclico, aza-bicicloalquilo y aza-bicicloalquenilo están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de Ra, grupos -alquil C1-4-CN, o grupos -alquil C1-4-C(O)NR'Rö en donde R' y Rö son iguales o diferentes y se seleccionan de átomos de hidrogeno y grupos alquilo lineales o ramificados C1-4 y los grupos alquilo no están sustituidos o están sustituidos con uno o más sustituyentes seleccionados de Rb; o R8 representa un grupo -SR13, -SOR13, -S(O)2R13, - S(O)2NR13R14, -NR13S(O)2R14, -NR13S(O)2NR14, -OR13, -C(O)OR13, -O-C(O)R13, -C(O)-(CH2)n-R13, -NR13R14, -C(O)-(CH2)n-NR13R14, -NR13C(O)-(CH2)n-R14, o -NR13C(O)-(CH2)n-NR14R15, en donde n es 0, 1 o 2, o R8 junto con R5 y el átomo de nitrogeno al que R5 está unido forman un grupo heterocíclico saturado, de 4 a 10 miembros, que contiene, como heteroátomos, uno o dos átomos de nitrogeno y que está sustituido con un grupo alquilo lineal o ramificado C1-6, un grupo arilo monocíclico o policíclico C5-14, un grupo heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, un grupo heterocíclico de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, -SOR10, -C(O)-(CH2)n-R10, o -C(O)-(CH2)n-NR10R11, en donde cada n es 0, 1 o 2, en donde los grupos alquilo, arilo, heteroarilo y heterocíclico están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de un átomo de halogeno, un grupo hidroxi, ciano, alquilo lineal o ramificado C1-6 o un grupo haloalquilo C1-4, y en donde los grupos alquilo están no sustituidos o sustituidos con uno o más sustituyentes seleccionados de un átomo de halogeno, un grupo hidroxi, ciano o un grupo haloalquilo C1-4, siempre que cuando m es cero, R8 es distinto de un grupo -SR13, -SOR13, -S(O)2R13, -S(O)2NR13R14, -NR13S(O)2R14, -NR13S(O)2NR14, -OR13, -O-C(O)R13, -NR43R14, -NR13C(O)-(CH2)n-R14 o -NR13C(O)-(CH2)n-NR14R15, en donde Ra es un átomo de halogeno, un grupo ciano, hidroxi, alquilo lineal o ramificado C1-6, donde dicho grupo alquilo está no sustituido o sustituido con uno o más grupos ciano, haloalquilo C1-4, hidroxialquilo C1-4, cicloalquilo C3-7 o un grupo cicloalquenilo C3-7, arilo monocíclico o policíclico C5-14, donde dicho grupo arilo está no sustituido o sustituido con uno o más sustituyentes seleccionados de un átomo de halogeno o un grupo ciano, un grupo heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, donde dicho grupo heteroarilo está no sustituido o sustituido con uno o más sustituyentes seleccionados de un átomo de halogeno o un grupo ciano, un grupo heterocíclico de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, -SR10, -SOR10, -S(O)2R10, -S(O)2NR10R11, -NR10S(O)2R11, -NR10S(O)2NR11, -OR10, -C(O)OR10, -C(O)-CH2-OR10, -C(O)-(CH2)n-O-(CH2)pR10, -C(O)-(CH2)n-O-(CH2)pO-R10, -O-C(O)R10, -C(O)-(CH2)n-R10, -NR10R11, -C(O)-(CH2)n-NR10R11, -R10C(O)-(CH2)n-NR11R12, -C(alquil C1-4)2-C(O)-(CH2)n-NR10R11, -NR10C(O)-(CH2)n-R11 o -NR10C(O)-(CH2)n-NR11R12, en donde cada n es 0 o un numero entero de 1 a 5, y en donde p es un numero entero de 1 a 3; Rb es un grupo ciano, hidroxi, alquilo lineal o ramificado C1-6, haloalquilo C1-4, hidroxialquilo C1-4, cicloalquilo C3-7 o un grupo cicloalquenilo C3-7, un grupo arilo monocíclico o policíclico C5-14, donde dicho grupo arilo está no sustituido o sustituido con uno o más sustituyentes seleccionados de un átomo de halogeno o un grupo ciano, heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, donde dicho grupo heteroarilo está no sustituido o sustituido con uno o más sustituyentes seleccionados de un átomo de halogeno o un grupo ciano, un grupo heterocíclico de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, un grupo -SR10, -SOR10, -S(O)2R10, -S(O)2NR10R11, -NR10S(O)2R11, -NR10S(O)2NR11, -OR10, -C(O)OR10, -C(O)-CH2-OR10, -C(O)-(CH2)n-O-(CH2)pR10, -C(O)-(CH2)n-O-(CH2)pO-R10, -O-C(O)R10, -C(O)-(CH2)n-R10, -NR10R11, -C(O)-(CH2)n-NR10R11, -R10C(O)-(CH2)n-NR11R12, -C(alquil C1-4)2-C(O)-(CH2)n-NR10R11, -NR10C(O)-(CH2)n-R11 o -NR10C(O)-(CH2)n-NR11R12, en donde cada n es 0 o un numero entero de 1 a 5, y en donde p es un numero entero de 1 a 3; cada uno de R10, R11 y R12 independientemente representa un átomo de hidrogeno, un grupo ciano, alquilo lineal o ramificado C1-6, haloalquilo C1-4, hidroxialquilo C1-6, alcoxicarbonilo C1-4, cicloalquilo C3-7, fenilo, un grupo -(hidroxialquil C1-4)-(fenilo), -C(O)-(fenilo), un grupo heteroarilo monocíclico de 5 a 6 miembros que contiene 1, 2, 3 o 4 heteroátomos seleccionados de N, O y S, un grupo heterocíclico de 5 a 6 miembros que contiene 1, 2 o 3 heteroátomos seleccionados de átomos de oxígeno y nitrogeno, un grupo heterocicloalquil C3-7 cetona que contiene 1, 2 o 3 átomos de nitrogeno, un grupo bicíclicClaim 1: A compound of formula (1), or a pharmaceutically acceptable salt, or solvate, or N-oxide or stereoisomer thereof, for use in the treatment of a pathological condition or disease susceptible to improvement by inhibition of Janus kinases (JAK ) where, m is 0 or an integer from 1 to 3; Z is an oxygen atom or an NR5 group; X and Y independently represent a nitrogen atom or a -CR9 group, where at least one of X and Y represents a nitrogen atom; each of R1, R2, R3, R4 and R9 independently represents a hydrogen atom, halogen, cyano, linear or branched C1-8 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 hydroxyalkyl , C3-10 cycloalkyl, C3-10 cycloalkenyl, C1-4 alkyl-C3-7 cycloalkyl, C5-14 monocyclic or polycyclic aryl, a 5- to 14-membered heteroaryl group containing at least one heteroatom selected from O, S and N , a 5 to 14 membered heterocyclic group containing at least one heteroatom selected from O, S and N, a bicyclic group containing a C5-9 monocyclic aryl or heteroaryl group directly attached to a 5 to 9 membered cycloalkyl or heterocyclic group , wherein said heteroaryl or heterocyclic group contains at least one heteroatom selected from O, S and N, an aza-bicycloalkyl group having up to 12 carbon atoms or an aza-bicycloalkenyl group having up to 12 carbon atoms, wherein the groups alkenyl, alkynyl, haloalkyl, hydroxyalk uyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclic, bicyclic, aza-bicycloalkyl and aza-bicycloalkenyl are unsubstituted or substituted with one or more substituents selected from the Ra substituents, and the alkyl groups are unsubstituted or substituted with one or more substituents selected from Rb; or R1, R2, R3, R4 and R9 independently represent a group -SR13, -SOR13, -S (O) 2R13, -S (O) 2NR13R14, -NR13S (O) 2R14, -NR13S (O) 2NR14, -OR13 , -C (O) OR13, -OC (O) R13, -C (O) - (CH2) n-R13, -NR13R14, -C (O) - (CH2) n-NR13R14, -NR13C (O) - (CH2) n-R14 or a group -NR13C (O) - (CH2) n-NR14R15, where each n is 0, 1 or 2; or in which case where two adjacent -CR9 groups are present, the two adjacent -CR9 groups and the carbon atoms to which they are attached optionally form a C5-12 aryl group or a heteroaryl, cycloalkyl or heterocyclic group of 4 to 12 members, wherein said heteroaryl and heterocyclic groups contain at least one heteroatom selected from O, S and N, wherein said aryl, heteroaryl, cycloalkyl and heterocyclic groups are unsubstituted or substituted with one or more substituents selected from a halogen atom, a C1-6 linear or branched alkyl group, a C5-14 monocyclic or polycyclic aryl group, 5-14 membered heteroaryl containing at least one heteroatom selected from O, S and N, or 5-14 membered heterocyclic containing the minus a heteroatom selected from O, S and N, wherein the alkyl, aryl, heteroaryl and heterocyclic substituents are unsubstituted or substituted with one or more substituents selected from a halogen atom, a hydroxy, cyano, C1-6 linear or branched alkyl group or a C1-4 haloalkyl group; R5 represents a hydrogen atom, a C1-6 linear or branched alkyl group optionally substituted with one or more substituents selected from a hydroxy, cyano, C1-4 haloalkyl, C1-4 hydroxyalkyl, C3-10 cycloalkyl, a phenyl group or a 6-membered saturated heterocyclic ring containing N, or R5 represents a group -S (O) 2R10, a group -S (O) 2NR10R11, -C (O) OR10, -C (O) - (CH2) n- R10 or -C (O) - (CH2) n-NR10R11; R6 and R7 each independently represent a hydrogen atom or a C1-6 linear or branched alkyl group optionally substituted with one or more substituents selected from a hydroxy, cyano, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy group, C1-4 alkoxycarbonyl, C3-7 cycloalkyl, a phenyl group or a 6-membered N-containing heterocyclic ring; R8 represents a hydrogen atom, halogen, a cyano group, linear or branched C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-6 alkyl C1-alkoxy 4, C3-10 cycloalkyl, C3-10 cycloalkenyl, C5-14 monocyclic or polycyclic aryl, a 5 to 14 membered heteroaryl group containing at least one heteroatom selected from O, S and N, a 5 to 14 membered heterocyclic group containing at least one heteroatom selected from O, S and N, C3-7 heterocycloalkyl ketone containing 1, 2 or 3 nitrogen atoms, a bicyclic group containing a C5-9 monocyclic aryl or heteroaryl group directly attached to a cycloalkyl group or 5- to 9-membered heterocyclic, wherein said heteroaryl or heterocyclic group contains at least one heteroatom selected from O, S and N, an aza-bicycloalkyl group having up to 12 carbon atoms or an aza-bicycloalkenyl group having up to 12 atoms carbon, where alkenyl groups, alq uinyl, haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclic, heterocycloalkyl ketone, bicyclic, aza-bicycloalkyl and aza-bicycloalkenyl are unsubstituted or substituted with one or more substituents selected from Ra, C1-4-CN alkyl groups , or C1-4-C (O) NR'Rö alkyl groups where R 'and Rö are the same or different and are selected from hydrogen atoms and C1-4 linear or branched alkyl groups and the alkyl groups are not substituted or are substituted with one or more substituents selected from Rb; or R8 represents a group -SR13, -SOR13, -S (O) 2R13, - S (O) 2NR13R14, -NR13S (O) 2R14, -NR13S (O) 2NR14, -OR13, -C (O) OR13, - OC (O) R13, -C (O) - (CH2) n-R13, -NR13R14, -C (O) - (CH2) n-NR13R14, -NR13C (O) - (CH2) n-R14, or - NR13C (O) - (CH2) n-NR14R15, where n is 0, 1 or 2, or R8 together with R5 and the nitrogen atom to which R5 is attached form a saturated heterocyclic group, 4 to 10 members, which it contains, as heteroatoms, one or two nitrogen atoms and which is substituted with a C1-6 linear or branched alkyl group, a C5-14 monocyclic or polycyclic aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom selected from O, S and N, a 5- to 14-membered heterocyclic group containing at least one heteroatom selected from O, S and N, -SOR10, -C (O) - (CH2) n-R10, or -C ( O) - (CH2) n-NR10R11, wherein each n is 0, 1 or 2, wherein the alkyl, aryl, heteroaryl and heterocyclic groups are unsubstituted or substituted with one or more substituents selected from a halogen atom, a hydroxy, cyano, linear or branched C1-6 alkyl group or a C1-4 haloalkyl group, and wherein the alkyl groups are unsubstituted or substituted with one or more substituents selected from a halogen atom, a hydroxy group, cyano or a C1-4 haloalkyl group, provided that when m is zero, R8 is different from a group -SR13, -SOR13, -S (O) 2R13, -S (O) 2NR13R14, -NR13S (O) 2R14, -NR13S (O) 2NR14, -OR13, -OC (O) R13, -NR43R14, -NR13C (O) - (CH2) n-R14 or -NR13C (O) - (CH2) n-NR14R15, where Ra is a halogen atom, a cyano, hydroxy, linear or branched C1-6 alkyl group, wherein said alkyl group is unsubstituted or substituted with one or more cyano, C1-4 haloalkyl, C1-4 hydroxyalkyl, C3- cycloalkyl groups. 7 or a C3-7 cycloalkenyl, monocyclic or C5-14 polycyclic aryl group, wherein said aryl group is unsubstituted or substituted with one or more substituents selected from a halogen atom or a cyano group, a 5-14 member heteroaryl group os containing at least one heteroatom selected from O, S and N, wherein said heteroaryl group is unsubstituted or substituted with one or more substituents selected from a halogen atom or a cyano group, a 5- to 14-membered heterocyclic group containing at least one heteroatom selected from O, S and N, -SR10, -SOR10, -S (O) 2R10, -S (O) 2NR10R11, -NR10S (O) 2R11, -NR10S (O) 2NR11, -OR10, - C (O) OR10, -C (O) -CH2-OR10, -C (O) - (CH2) nO- (CH2) pR10, -C (O) - (CH2) nO- (CH2) pO-R10, -OC (O) R10, -C (O) - (CH2) n-R10, -NR10R11, -C (O) - (CH2) n-NR10R11, -R10C (O) - (CH2) n-NR11R12, - C (C1-4 alkyl) 2-C (O) - (CH2) n-NR10R11, -NR10C (O) - (CH2) n-R11 or -NR10C (O) - (CH2) n-NR11R12, where each n is 0 or an integer from 1 to 5, and where p is an integer from 1 to 3; Rb is a cyano, hydroxy, C1-6 linear or branched alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C3-7 cycloalkyl or a C3-7 cycloalkenyl group group, a C5-14 monocyclic or polycyclic aryl group, wherein said aryl group is unsubstituted or substituted with one or more substituents selected from a halogen atom or a cyano, 5-14 membered heteroaryl group containing at least one heteroatom selected from O, S and N, wherein said heteroaryl group is unsubstituted or substituted with one or more substituents selected from a halogen atom or a cyano group, a 5- to 14-membered heterocyclic group containing at least one heteroatom selected from O, S and N, a group -SR10, -SOR10, -S (O) 2R10, -S (O) 2NR10R11, -NR10S (O) 2R11, -NR10S (O) 2NR11, -OR10, -C (O) OR10, -C (O) -CH2-OR10, -C (O ) - (CH2) nO- (CH2) pR10, -C (O) - (CH2) nO- (CH2) pO-R10, -OC (O) R10, -C (O) - (CH2) n-R10, -NR10R11, -C (O) - (CH2) n-NR10R11, -R10C (O) - (CH2) n-NR11R12, -C (C1-4 alkyl) 2-C (O) - (CH2) n-NR10R11 , -NR10C (O ) - (CH2) n-R11 or -NR10C (O) - (CH2) n-NR11R12, where each n is 0 or an integer from 1 to 5, and where p is an integer from 1 to 3; each of R10, R11 and R12 independently represents a hydrogen atom, a cyano group, linear or branched C1-6 alkyl, C1-4 haloalkyl, C1-6 hydroxyalkyl, C1-4 alkoxycarbonyl, C3-7 cycloalkyl, phenyl, a group - (hydroxyC 1-4 alkyl) - (phenyl), -C (O) - (phenyl), a 5- to 6-membered monocyclic heteroaryl group containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, a 5- to 6-membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from oxygen and nitrogen atoms, a C3-7 heterocycloalkyl ketone group containing 1, 2 or 3 nitrogen atoms, a bicyclic group

ARP100104869A 2009-12-24 2010-12-22 IMIDAZO DERIVATIVES [1,2A] PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THEMSELVES IN MYELOPROLIFERATIVE DISORDERS, LEUKEMIA AND IMMUNOLOGICAL AND INFLAMMATORY DISEASES. AR079689A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382303A EP2338888A1 (en) 2009-12-24 2009-12-24 Imidazopyridine derivatives as JAK inhibitors

Publications (1)

Publication Number Publication Date
AR079689A1 true AR079689A1 (en) 2012-02-15

Family

ID=42136251

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104869A AR079689A1 (en) 2009-12-24 2010-12-22 IMIDAZO DERIVATIVES [1,2A] PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THEMSELVES IN MYELOPROLIFERATIVE DISORDERS, LEUKEMIA AND IMMUNOLOGICAL AND INFLAMMATORY DISEASES.

Country Status (25)

Country Link
US (1) US20130216498A1 (en)
EP (2) EP2338888A1 (en)
JP (1) JP2013515688A (en)
KR (1) KR20120118459A (en)
CN (1) CN102695706A (en)
AR (1) AR079689A1 (en)
AU (1) AU2010335556A1 (en)
BR (1) BR112012015540A2 (en)
CA (1) CA2785113A1 (en)
CL (1) CL2012001379A1 (en)
CO (1) CO6541643A2 (en)
CR (1) CR20120334A (en)
EA (1) EA201200938A1 (en)
EC (1) ECSP12011910A (en)
GT (1) GT201200207A (en)
IL (1) IL219916A0 (en)
MX (1) MX2012007175A (en)
NZ (1) NZ599932A (en)
PE (1) PE20121482A1 (en)
SG (2) SG10201407927UA (en)
TW (1) TWI481608B (en)
UA (1) UA107951C2 (en)
UY (1) UY33130A (en)
WO (1) WO2011076419A1 (en)
ZA (1) ZA201203326B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33213A (en) 2010-02-18 2011-09-30 Almirall Sa PIRAZOL DERIVATIVES AS JAK INHIBITORS
MX2012012145A (en) * 2010-04-28 2012-11-21 Daiichi Sankyo Co Ltd [5,6] heterocyclic compound.
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
MX361136B (en) 2013-01-23 2018-11-28 Astrazeneca Ab Chemical compounds.
HUE035966T2 (en) * 2013-03-14 2018-05-28 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9868722B2 (en) 2013-12-10 2018-01-16 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex
WO2015091531A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Imidazolopyrimidin-2-yl derivatives as jak inhibitors
BR112016016421B1 (en) 2014-01-20 2022-10-18 Cleave Biosciences, Inc FUSED PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE
EP3116506B1 (en) * 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
TWI679205B (en) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 Pyrazolothiazole compounds and medicine
FR3030521B1 (en) * 2014-12-23 2019-07-26 Galderma Research & Development NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE AND COSMETICS
CN107428749B (en) * 2015-01-28 2020-07-24 上海复旦张江生物医药股份有限公司 Substituted imidazo [1,2- α ] pyridin-2-ylamine compounds, pharmaceutical compositions and methods of use thereof
TW201705961A (en) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors
CN108349972B (en) 2015-11-03 2021-06-08 施万生物制药研发Ip有限责任公司 JAK kinase inhibitor compounds for the treatment of respiratory diseases
TWI712604B (en) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 Crystal of compound with JAK inhibitory effect
WO2017216726A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CA2997772A1 (en) * 2017-03-09 2018-09-09 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine jak inhibitors
EP3609498A1 (en) 2017-05-01 2020-02-19 Theravance Biopharma R&D IP, LLC Methods of treatment using a jak inhibitor compound
KR20200115620A (en) * 2018-01-29 2020-10-07 메르크 파텐트 게엠베하 GCN2 inhibitors and uses thereof
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN112739689B (en) * 2018-12-07 2022-06-03 优迈特株式会社 Fluorine-containing pyrimidine compound and method for producing same
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3148227A1 (en) 2019-07-24 2021-01-28 Merck Patent Gmbh 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives
JP7109684B2 (en) * 2019-11-01 2022-07-29 ユニマテック株式会社 Fluorine-containing pyrimidine compound and method for producing the same
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4105210A4 (en) * 2020-02-12 2023-12-06 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound and production method therefor
CN115244044A (en) * 2020-03-25 2022-10-25 优迈特株式会社 Fluorine-containing pyrimidine compound and method for producing same
CA3226908A1 (en) * 2021-07-30 2023-02-02 Scott Bryan HOYT Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023239941A1 (en) * 2022-06-10 2023-12-14 Interline Therapeutics Inc. Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54128591A (en) 1978-03-25 1979-10-05 Kyowa Hakko Kogyo Co Ltd Cephalosporin analog
ATE209518T1 (en) 1995-06-21 2001-12-15 Asta Medica Ag MEDICINAL POWDER CARTRIDGE WITH INTEGRATED DOSING DEVICE AND POWDER INHALER
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
ES2310202T3 (en) * 2001-04-26 2009-01-01 EISAI R&D MANAGEMENT CO., LTD. CONDENSED CYCLING COMPOUND CONTAINING NITROGEN THAT HAS A PIRAZOLIL GROUP AS A SUBSTITUTING GROUP AND PHARMACEUTICAL COMPOSITION OF THE SAME.
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE10202940A1 (en) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Cartridge for a powder inhaler
CA2483084A1 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2195785B1 (en) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
CA2486183C (en) 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
ES2211344B1 (en) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2232306B1 (en) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
CA2549485A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
DE102004012070A1 (en) 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
PL2332940T3 (en) * 2004-03-30 2013-03-29 Vertex Pharma Azaindoles useful as inhibitors of JAK and other protein kinases
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
ES2251866B1 (en) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2251867B1 (en) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
RS52061B (en) 2005-02-04 2012-04-30 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
ES2296516B1 (en) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
AU2007259143A1 (en) 2006-06-08 2007-12-21 Amgen Inc. Benzamide derivatives and uses related thereto
AR063141A1 (en) 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
ATE542818T1 (en) * 2006-10-11 2012-02-15 Amgen Inc IMIDAZO AND TRIAZOLOPYRIDINE COMPOUNDS AND METHOD OF USE THEREOF
ES2302447B1 (en) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
JP5442449B2 (en) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド New compounds
ES2319596B1 (en) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS.
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
UY31272A1 (en) 2007-08-10 2009-01-30 Almirall Lab NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID
WO2009026254A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
WO2009054941A1 (en) * 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
AU2008343173A1 (en) * 2007-12-19 2009-07-09 Aj Park Pyrazolo [1,5-a] pyrimidines useful as JAK2 inhibitors
CA2710452A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds
KR101261514B1 (en) * 2008-02-25 2013-05-07 에프. 호프만-라 로슈 아게 Pyrrolopyrazine kinase inhibitors
FR2928150A1 (en) 2008-02-29 2009-09-04 Vetoquinol Sa Sa NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONES DERIVATIVES, THEIR PREPARATION AND APPLICATION AS ANTI-BACTERIANS
US8680113B2 (en) 2008-07-01 2014-03-25 Ptc Therapeutics, Inc. BMI-1 protein expression modulators
US8518952B2 (en) * 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors

Also Published As

Publication number Publication date
IL219916A0 (en) 2012-07-31
ZA201203326B (en) 2013-03-27
TWI481608B (en) 2015-04-21
JP2013515688A (en) 2013-05-09
CL2012001379A1 (en) 2012-10-12
SG10201407927UA (en) 2015-01-29
CR20120334A (en) 2012-10-05
AU2010335556A1 (en) 2012-05-31
GT201200207A (en) 2015-02-19
PE20121482A1 (en) 2012-11-05
KR20120118459A (en) 2012-10-26
CA2785113A1 (en) 2011-06-30
SG181439A1 (en) 2012-07-30
NZ599932A (en) 2014-08-29
WO2011076419A1 (en) 2011-06-30
UY33130A (en) 2011-06-30
EP2338888A1 (en) 2011-06-29
EA201200938A1 (en) 2013-02-28
EP2516436A1 (en) 2012-10-31
ECSP12011910A (en) 2012-07-31
MX2012007175A (en) 2012-07-04
UA107951C2 (en) 2015-03-10
BR112012015540A2 (en) 2019-09-24
US20130216498A1 (en) 2013-08-22
TW201130835A (en) 2011-09-16
CN102695706A (en) 2012-09-26
CO6541643A2 (en) 2012-10-16

Similar Documents

Publication Publication Date Title
AR079689A1 (en) IMIDAZO DERIVATIVES [1,2A] PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THEMSELVES IN MYELOPROLIFERATIVE DISORDERS, LEUKEMIA AND IMMUNOLOGICAL AND INFLAMMATORY DISEASES.
AR080187A1 (en) PIRAZOLIC DERIVATIVES CONDENSED WITH USEFUL NITROGEN HETEROYCLES IN THE TREATMENT OF INFLAMMATORY, IMMUNITY AND / OR MIELOPLOLIFERATIVE DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR086546A1 (en) DERIVATIVES OF 7H-PURIN-8 (9H) -ONA AS JAK INHIBITORS
AR081932A1 (en) DERIVATIVES OF HETEROARIL IMIDAZOLONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF NEOPLASIC AND AUTOINMUNE DISEASES
AR113964A1 (en) CARBAMOIL CYCLOHEXYL N-LINKED ACIDS OF TRIAZOLE AS ANTAGONISTS OF LPA
PE20220567A1 (en) NEW PIPERIDINIL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO6251243A2 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
AR095311A1 (en) 3-PIRIMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS MUTANT HDI INHIBITORS
AR064561A1 (en) DERIVATIVES OF 2-AZA-BICYCLE [3.1.0] HEXANE AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES RELATED TO GENERAL DYSFUNCTIONS OF THE OREXINE SYSTEM.
AR089671A1 (en) 1,4-DIHIDROPIRIMIDINAS 4,4-DISUSTITUIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
AR070459A1 (en) DERIVATIVES OF 2-AZA-BICYCLE- [2,2,1] HEPTANE
AR100691A1 (en) NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES OF THE SAME
AR081994A1 (en) DERIVATIVES OF [1,8] NAFTIRIDINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME FOR THE TREATMENT OF DISEASES INDICATED BY KINASES, IN PARTICULAR DIFFERENT TYPES OF CANCERES
PE20150399A1 (en) NEW PIRROL DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR087760A1 (en) HETEROCICLILAMINAS AS PI3K INHIBITORS
AR085489A1 (en) DERIVATIVES OF TRIAZOLOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM, INTERMEDIARIES OF SUCH PROCESS AND USE OF THE SAME FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
AR085602A1 (en) INHIBITORS OF KINASES, PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATION IN THE TREATMENT OF CANCERES AND AUTOIMMUNE DISORDERS
AR117102A1 (en) ARG1 AND / OR ARG2 INHIBITORS
AR071717A1 (en) PIRROLO [2,3-B] CHK1 AND CHK2 QUINASE INHIBITING PIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT AND PREVENTION OF CANCER.
AR077977A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
AR112216A1 (en) DERIVATIVES OF AZAQUINOLINE
AR089143A1 (en) SUBSTITUTED TRIAZOLOPIRIDINS WITH INHIBITING ACTIVITY OF TTK
AR088180A1 (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDA, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
AR089285A1 (en) BETULINA DERIVATIVES
AR085327A1 (en) HEPATITIS C VIRUS INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure